What to Expect at the CDD & AI for Biologics Forum?
Rapid advances in foundation models, protein design, and multi-objective optimization continued to reshape how biologics are discovered, optimized, and derisked throughout the industry. Yet a recurring theme across the field remained the challenge of translating promising AI/ML outputs into scalable, experimentally validated impact.
The CDD & AI for Biologics Summit brought together the biologics community at this pivotal moment, uniting techbio pioneers, biotech innovators, and pharma leaders to examine how AI/ML and computational approaches are being successfully operationalized across biologics R&D. Attendees explored applications spanning de novo biologics design, property prediction, and multi-objective optimization, with case studies covering everything from straightforward binders such as miniproteins to more complex modalities including bispecifics, multispecifics, and ADCs.
Through applied presentations, data-driven case studies, and wet-lab validated learnings, participants gained practical insights into advancing AI-enabled biologics from early discovery through lead optimization. The event highlighted strategies for reducing CMC risk, strengthening translational confidence, and accelerating the journey from computational prediction to therapeutic impact. Attendees left equipped with actionable knowledge, new collaborations, and a clearer roadmap for bringing AI-enabled biologics to patients faster.
What Set This Meeting Apart?
Understand how to deploy AI/ML for de novo biologics design and property prediction with Ordaos Bio, Takeda and VRG Therapeutics
Leverage CDD and AI/ML to predict and optimize leads for developability parameters, and identify liabilities with Insilico Medicine, AbbVie and Regeneron
Investigate AI/ML model use cases for complex biologics design across multispecifics and conjugated drug products with insights from GSK and 3T Biosciences
Supercharge molecular dynamics approaches with AI/ML models to reflect the folding energetics of biologics with Genentech and Amgen
Deep dive into data readiness and lab automation for AI-enabled biologics design, discovery and optimization with AI Proteins, insitro and the Institute for Protein Innovation
Gain a strategic overview of recent industry investments, data foundations and the IP landscape of AI/ML use cases for biologics discovery and design with insitro and UCB
Dive into the 2026 Program to Find:
- 20+ World-Class Computational & AI/ML-Guided Biologics Speakers with Expertise Spanning Discovery, Design & Optimization
- 8+ Hours of Unmatched Networking & Strategic Partnering Opportunities
- 2 Days of Exclusive Content Providing Best-in-Class AI/ML Use Cases & Insights
- 2 In-Conference Deep Dive Workshops Offering Perspectives on Data Readiness & Lab Automation for AI-Enabled Biologic Therapeutics Design
- A Focused, Industry-Lead Community of Top Techbio, Pharma & Biotech Organizations
Companies That Attended Include
Discover the 2026 Agenda
Catch the latest industry breakthroughs, emerging trends and exclusive insights by participating in our dynamic roundtables and panel discussions.
Prioritize Partnering With Us
As the field rapidly expands and matures, position yourself alongside leading solution providers to ensure your brand stands out as a premier choice, amid growing competition.
Join Your Community
Immerse yourself in critical conversations with like-minded experts spanning all stages of development, from in silico to de novo biologics design and developability optimization, and build invaluable connections.